IQ-AI Limited shares latest progress from Phase I glioblastoma clinical trial | News Direct

IQ-AI Limited shares latest progress from Phase I glioblastoma clinical trial

News release by IQ-AI Ltd

facebook icon linkedin icon twitter icon pinterest icon email icon New York | July 19, 2023 01:03 PM Eastern Daylight Time

 

Dr Jennifer Connelly, the Principal Investigator (PI) of the IQ-AI Limited sponsored Phase I Clinical Trial that is being conducted at the Medical College of Wisconsin, joins Proactive's Natalie Stoberman to discuss the latest updates from its treatment for recurring glioblastoma patients.

IQ-AI Ltd, the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively.

 

Contact Details

 

Proactive Investors

 

+1 347-449-0879

 

na-editorial@proactiveinvestors.com

Tags

ProactiveInvestorsIQAILimitedclinicaltrialglioblastomainvestinvestinginvestmentinvestorstockmarketstocksstockstockmarketnews